Loewenbaum Group Cuts Stake to 24.99% After Removing Three Members
CLGN sits 15% above its 52-week low of $0.27.
Summary
The Loewenbaum family group reduced its CollPlant stake to 24.99% after removing three members from its reporting group, and transferred funds for Series B warrant exercise without actually exercising them.
Key Events · Ownership and Investor Activity · CLGN
-
Group Stake Reduced to 24.99%
The Loewenbaum group removed Nachum Shamir, Patrick Chalmers, and Reginald J. Hargrove from its reporting group, reducing aggregate beneficial ownership from 33.0% to 24.99%.
-
Series B Warrant Funds Transferred
The Loewenbaum 1992 Trust transferred funds equal to the aggregate exercise price of the Series B Warrants to the company on August 20, 2026, but no warrants were exercised; funds are held in abeyance.
-
Beneficial Ownership Limitation Maintained
The group's stake is capped at 24.99% by the beneficial ownership limitation on warrant exercise, and the removal of members keeps the group below this threshold.
-
Prior Stake Increases
The group had previously increased its stake from 18.6% to 33.0% through warrant exercises in July 2026, as disclosed in prior 13D/A filings.
Analysis · CLGN · Industrial Applications And Services
The Loewenbaum family group has removed Nachum Shamir, Patrick Chalmers, and Reginald J. Hargrove from its reporting group, reducing its aggregate beneficial ownership from 33.0% to 24.99%. This is a material change in the group's composition and stake, though the group remains the largest shareholder. Separately, the Loewenbaum 1992 Trust transferred funds to the company for the Series B warrant exercise price but has not exercised the warrants, leaving the funds in abeyance. This suggests the group is positioning to maintain its stake below the 24.99% beneficial ownership limitation while retaining the ability to exercise warrants later.
At the time of this filing, CLGN was trading at $0.31 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.27 to $3.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.